Search Results - "Hebbar, M."

The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family by Skrypek, N, Duchêne, B, Hebbar, M, Leteurtre, E, van Seuningen, I, Jonckheere, N

“…The fluorinated analog of deoxycytidine, Gemcitabine (Gemzar), is the main chemotherapeutic drug in pancreatic cancer, but survival remains weak mainly because…”
Get full text

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer by Deplanque, G., Demarchi, M., Hebbar, M., Flynn, P., Melichar, B., Atkins, J., Nowara, E., Moyé, L., Piquemal, D., Ritter, D., Dubreuil, P., Mansfield, C.D., Acin, Y., Moussy, A., Hermine, O., Hammel, P.

“…Masitinib is a selective oral tyrosine–kinase inhibitor. The efficacy and safety of masitinib combined with gemcitabine was compared against single-agent…”
Get full text

A homozygous nonsense variant in IFT52 is associated with a human skeletal ciliopathy by Girisha, K. M., Shukla, A., Trujillano, D., Bhavani, G. S., Hebbar, M., Kadavigere, R., Rolfs, A.

“…Intraflagellar transport (IFT) is vital for the functioning of primary cilia. Defects in several components of IFT complexes cause a spectrum of ciliopathies…”
Get full text

Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV by Lévi, F.A., Boige, V., Hebbar, M., Smith, D., Lepère, C., Focan, C., Karaboué, A., Guimbaud, R., Carvalho, C., Tumolo, S., Innominato, P., Ajavon, Y., Truant, S., Castaing, D., De Baere, T., Kunstlinger, F., Bouchahda, M., Afshar, M., Rougier, P., Adam, R., Ducreux, M.

“…Systemic chemotherapy typically converts previously unresectable liver metastases (LM) from colorectal cancer to curative intent resection in ∼15% of patients…”
Get full text

Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child‐Pugh score by Hollebecque, A., Cattan, S., Romano, O., Sergent, G., Mourad, A., Louvet, A., Dharancy, S., Boleslawski, E., Truant, S., Pruvot, F.‐R., Hebbar, M., Ernst, O., Mathurin, P.

“…Aliment Pharmacol Ther 2011; 34: 1193–1201 Summary Background  Sorafenib increases median survival and time to radiological progression in patients with…”
Get full text

Laparoscopic resection vs. open liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: a case-matched study by Truant, S., Bouras, A. F., Hebbar, M., Boleslawski, E., Fromont, G., Dharancy, S., Leteurtre, E., Zerbib, P., Pruvot, F. R.

“…Background Studies that compare laparoscopic to open liver resection for hepatocellular carcinoma (HCC) in cirrhotic patients are rare and may have suffered…”
Get full text

Tumor size of hepatocellular carcinoma in noncirrhotic liver: A controversial predictive factor for outcome after resection by Truant, S, Boleslawski, E, Duhamel, A, Bouras, A.-F, Louvet, A, Febvay, C, Leteurtre, E, Huet, G, Zerbib, P, Dharancy, S, Hebbar, M, Pruvot, F.-R

“…Abstract Background Hepatocellular carcinoma in noncirrhotic liver (NC-HCC) presents usually with large size, which is seen as a contraindication to liver…”
Get full text

Safety and efficacy of folfirinox in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis by Baldini, C, Escande, A, Bouché, O, El Hajbi, F, Volet, J, Bourgeois, V, Renaut Vantroys, T, Ploquin, A, Desauw, C, Hebbar, M

“…Abstract Background FOLFIRINOX is a polychemotherapy regimen currently used to treat inoperable pancreatic cancer in patients with a good performance status…”
Get full text

Laser application in laparoscopic CBD exploration in management of difficult CBD stones by Farag, S, Singh, K, Hebbar, M

Get full text

Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases by Truant, S., Huglo, D., Hebbar, M., Ernst, O., Steinling, M., Pruvot, F.-R.

“…Background: The aim of this study was to assess the additional value of information provided by positron emission tomography (PET) with…”
Get full text

1326 Folfirinage: Tolerance and efficacy of folfirinox in elderly patients with advanced pancreatic adenocarcinoma by Baldini, C, Escande, A, Bouché, O, Bourgeois, V, Renaut-Vantroys, T, Ploquin, A, Desauw, C, Hebbar, M

Get full text

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial by Hebbar, M., Chibaudel, B., André, T., Mineur, L., Smith, D., Louvet, C., Dutel, J.L., Ychou, M., Legoux, J.L., Mabro, M., Faroux, R., Auby, D., Brusquant, D., Khalil, A., Truant, S., Hadengue, A., Dalban, C., Gayet, B., Paye, F., Pruvot, F.R., Bonnetain, F., Taieb, J., Brucker, P., Landi, B., Flesch, M., Carola, E., Martin, P., Vaillant, E., de Gramont, A.

“…The sequential FOLFOX7–FOLFIRI combination is not superior to FOLFOX4 in colorectal cancer patients with resectable metastases. Patients with synchronous…”
Get full text

2294 Growth modulation index (GMI) to assess salvage chemotherapy benefit after FOLFIRINOX progression in metastatic pancreatic adenocarcinoma by Ducoulombier, A, Quintin, J, Desjardin, M, Hautefeuille, V, Desauw, C, Parzy, A, Bouche, O, Chauffert, B, Clisant, S, El Hajbi, F, Becouarn, Y, Bennouna, J, Hebbar, M, Penel, N, Adenis, A

Get full text

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer by Conroy, T, Hebbar, M, Bennouna, J, Ducreux, M, Ychou, M, Llédo, G, Adenis, A, Faroux, R, Rebischung, C, Kockler, L, Douillard, J Y

“…Background: A phase-III trial showed the non-inferiority of oral capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6)…”
Get full text

2305 Randomized phase 2/3 trial of transcatheter arterial chemoembolization (TACE) plus sunitinib or placebo in patients with hepatocellular carcinoma (HCC) (PRODIGE 16/SATURNE study): Results of the Phase II part by Hebbar, M, Heurgue-Berlot, A, Boige, V, Le Malicot, K, Bernard-Chabert, B, Marcus, C, Dharancy, S, Sergent, G, Perarnau, J.M, Ehrhard, F, Ollivier-Hourmand, I, Vergniol, J, Michel, P, Edeline, J, Rinaldi, Y, Seitz, J.F, Lepage, C, De Baere, T

Get full text

190 The Mucin MUC4-mediated Chemoresistance of Human Pancreatic Cancer Cells to Gemcitabine and FOLFIRINOX by Skrypek, N, Duchene, B, Hebbar, M, Leteurtre, E, Van Seuningen, I, Jonchkeere, N

Get full text

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial by Hebbar, M., Chibaudel, B., André, T., Mineur, L., Smith, D., Louvet, C., Dutel, J.L., Ychou, M., Legoux, J.L., Mabro, M., Faroux, R., Auby, D., Brusquant, D., Khalil, A., Truant, S., Hadengue, A., Dalban, C., Gayet, B., Paye, F., Pruvot, F.R., Bonnetain, F., de Gramont, A.

Get full text

Prognostic Value of the Type I Growth Factor Receptors in a Large Series of Human Primary Breast Cancers Quantified with a Real-Time Reverse Transcription-Polymerase Chain Reaction Assay by PAWLOWSKI, Valérie, REVILLION, Francoise, HEBBAR, Mohamed, HORNEZ, Louis, PEYRAT, Jean-Philippe

“…We measured the expression of the type I growth factor receptor gene family [epidermal growth factor receptor (EGFR), c-erbB-2, c-erbB-3 and c-erbB-4] in a…”
Get full text

Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study by André, T., Tournigand, C., Mineur, L., Fellague-Chebra, R., Flesch, M., Mabro, M., Hebbar, M., Postel Vinay, S., Bidard, F.C., Louvet, C., de Gramont, A.

“…Background: Oxaliplatin stop and go in combination with leucovorin and 5-fluorouracil has been successfully used in a previous study (OPTIMOX1) in metastatic…”
Get full text

Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6 by Perrocheau, G, Bennouna, J, Ducreux, M, Hebbar, M, Ychou, M, Lledo, G, Conroy, T, Dominguez, S, Faroux, R, Florentin, V, Douillard, J Y

“…In a recent randomized study, we demonstrated that XELOX (oxaliplatin + oral capecitabine) was well tolerated and not inferior in terms of efficacy to the…”
Get more information